Opinion|Videos|February 24, 2025
New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Ruxolitinib
Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Now let’s talk about some of the latest treatment advances in pediatric atopic dermatitis, starting with topicals. Discuss the topical treatment options that are newly available or on the horizon, including how they work to treat atopic dermatitis as well as efficacy and safety:
- Ruxolitinib cream
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
5